Product portfolio

At present, Biogen Idec Canada’s focus is in the therapeutic areas of Multiple Sclerosis and Hemophilia. Biogen Idec strives to be a pioneer in the research and development of advanced therapies for these disease areas.

Biogen Idec Canada currently has four Multiple Sclerosis therapies on the market, and one therapy each for Hemophilia A and Hemophilia B.

Links to comprehensive information about our products are listed below, in the form of a document known as a product monograph.  This information has been approved by Health Canada and should be read and discussed in consultation with a health care professional. 

Multiple Sclerosis

AVONEX® (interferon beta-1a)

FAMPYRA® (fampridine)

TECFIDERATM (dimethyl fumarate)

TYSABRI® (natalizumab)

Hemophilia

ALPROLIXTM (coagulation factor IX (recombinant), Fc fusion protein)

ELOCTATETM (antihemophilic factor (recombinant BDD), Fc fusion protein)